Eli Lilly: The Weight‑Loss Leader With More Upside If Execution Holds

Eli Lilly and Company (NYSE: LLY) has seen its stock soar roughly 47 % since the author’s prior analysis, surpassing an $800 price target and reaching all‑time highs near $1,030. The company’s dominance in the obesity‑treatment market – particularly via drugs such as Zepbound and Mounjaro – is driving both top‑ and bottom‑line growth. The bullish view rests on three key pillars: first, Lilly’s leadership in the rapidly expanding obesity/GLP‑1 market; second, its strong U.S. dominance and premium margin profile; and third, the potential undervaluation if its growth targets are achieved. To reflect this confidence, the author raises the price target to $1,165, applying a conservative FY 2027 EPS estimate combined with a 30× earnings multiple. Yet, the upside hinges on execution. As the article notes, while Lilly is well placed, realizing the full potential depends on maintaining its growth trajectory, defending market share, and navigating regulatory and competitive risks. #EliLilly #WeightLossDrugs #PharmaStocks #ObesityTreatment #SlimScan #GrowthStocks #CANSLIM